TABLE 1.
Change from baseline to 1 week of treatment in cerebrospinal fluid MMP-9 and TIMP-1 concentrations and their molar ratio compared with qualitative dataa
| Variableb | Median (IQR) changec in: |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| MMP-9 (n = 50) |
TIMP-1 (n = 62) |
MMP-9/TIMP-1 MR (n = 46) |
|||||||
| Yes | No | P | Yes | No | P | Yes | No | P | |
| Female (n = 31) | −88 (28) | −90 (37) | 0.95 | 91 (702) | −8 (398) | 0.12 | −95 (14) | −88 (24) | 0.37 |
| Severe malnutritiond (n = 15) | −80 (44) | −91 (26) | 0.31 | 57 (649) | 46 (520) | 0.73 | −88 (36) | −91 (14) | 0.44 |
| HIV positive (n = 5) | −91 (73) | −89 (26) | 0.85 | −8 (284) | 76 (611) | 0.56 | −98 (93) | −91 (17) | 0.83 |
| Etiology | 0.10 | 0.31 | 0.03 | ||||||
| Haemophilus influenzae (n = 15) | −80 (70) | −3 (549) | −88 (19) | ||||||
| Streptococcus pneumoniae (n = 18) | −92 (25) | 362 (680) | −98 (12) | ||||||
| Neisseria meningitidis (n = 4) | −94 (8) | 201 (867) | −99 (7) | ||||||
| Undisclosed (n = 13) | −83 (28) | −3 (250) | −85 (37) | ||||||
| Cefotaxime as infusion (n = 23) | −90 (26) | −89 (30) | 0.68 | 181 (667) | 2 (491) | 0.17 | −95 (19) | −89 (20) | 0.59 |
| Seizures during stay (n = 26) | −83 (27) | −90 (34) | 0.67 | 9 (569) | 91 (548) | 0.57 | −92 (37) | −88 (16) | 0.55 |
| Death (n = 3) | −26 (10) | −90 (26) | 0.02 | 116 (535) | 51(552) | 0.57 | −50 (58) | −91 (15) | 0.11 |
| Severe neurologic sequelae (n = 8) | −72 (25) | −90 (26) | 0.58 | −42 (25) | 89 (598) | 0.04 | −88 (60) | −95 (14) | 0.15 |
| Deafness (n = 6) | −95 (18) | −90 (26) | 0.36 | 15 (234) | 72 (682) | 0.62 | −97 (11) | −91 (17) | 0.61 |
a
Data analyzed with the Mann-Whitney U test and Kruskal-Wallis test.
b
Numbers in parentheses are the number of patients who have the described condition.
c
Percent change from admission to day 7 of treatment; yes, population with variable; no, population without variable.
d
Weight/age less than 2 standard deviations below the mean.